Follow-The-Filings

ADCT Adc Therapeutics SA

Health Care SHS Equity as of 2026 Q2 among managers we track

Bought by 2 featured managers in 2026 Q2

  • 2 Owners
  • Max 0.1%
  • $831K
  • 1 new 1 add

ADCT (Adc Therapeutics SA) is held in 2 featured 13F books as of 2026 Q2. James Silverman - Opaleye Management is the largest tracked holder by portfolio weight (0.07%). In 2026 Q2 filings, 1 manager opened new positions and 1 added. Figures are as-filed 13F, not free float.

Who owns this now

Largest portfolio weights among featured holders · max 0.1% (James Silverman - Opaleye Management) · not free-float ownership

  1. James Silverman New 0.07%
  2. Nathan Fischel Add 0.02%

Who owns ADCT

sorted by value · long equity only · current book 2026 Q2 · open a manager for their book

History
James Silverman - Opaleye Management 0.07% New 0.07% 700,000 $749K History
Nathan Fischel - Dafna Capital Management 0.02% Add +6.9% 77,081 $82K History

2 current · options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

SEC filings

Recent issuer filings from EDGAR · 18 shown · open Filing / Doc on SEC.gov

Filed Form Detail Links
8-K 2.02,7.01,9.01 Filing Doc
10-Q Filing Doc
8-K 5.02 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
8-K 5.07,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
DEFA14A FORM DEFA14A Filing Doc
424B3 FORM 424B3 Filing Doc
424B3 FORM 424B3 Filing Doc
8-K 2.02,9.01 Filing Doc
10-K Filing Doc
8-K 1.01,3.02,9.01 Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 2.02,7.01 Filing Doc
424B3 FORM 424B3 Filing Doc
8-K 8.01 Filing Doc

Insider forms

Form 3 / 4 / 5 from EDGAR · 5 rows shown

Filed Form Detail Links
4 Period Jun 30, 2026 · 4 forms Filing Doc
4 Period Jun 1, 2026 · 7 forms Filing Doc
4 Period Mar 31, 2026 Filing Doc
4 Period Feb 13, 2026 · 5 forms Filing Doc
4 Period Dec 6, 2025 · 5 forms Filing Doc

Updated about 2 months ago Source: SEC EDGAR submissions All on EDGAR

Financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $69.06M — —
Gross profit * $66.53M — —
Gross margin * 96.3% — —
Net income -$240.05M -$157.85M -$142.62M
Net margin * -347.6% — —

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $336.29M $307.39M $306.34M
Total non-current assets * $18.49M $14.59M $16.82M
Total assets $354.78M $321.98M $323.15M
Total current liabilities $67.67M $80.47M $70.16M
Total non-current liabilities * $435.36M $444.15M $438.82M
Total equity -$148.25M -$202.64M -$185.83M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$118.69M -$123.84M -$141.17M
Cash from investing -$3.22M -$0.867M $0.395M
Cash from financing $73.88M $97.05M $150.94M
Net change in cash * -$48.03M -$27.65M $10.17M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

Ownership over time

filing count by report period · click a bar for that quarter’s holders